PHAT (Phathom Pharmaceuticals) Days Sales Outstanding : 120.24 (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Phathom Pharmaceuticals Days Sales Outstanding?

Phathom Pharmaceuticals's average Accounts Receivable for the three months ended in Mar. 2025 was $37.58 Mil. Phathom Pharmaceuticals's Revenue for the three months ended in Mar. 2025 was $28.52 Mil. Hence, Phathom Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2025 was 120.24.

The historical rank and industry rank for Phathom Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

PHAT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 98.96 Med: 504.84 Max: 876.11
Current: 98.96

During the past 7 years, Phathom Pharmaceuticals's highest Days Sales Outstanding was 876.11. The lowest was 98.96. And the median was 504.84.

PHAT's Days Sales Outstanding is ranked worse than
67.38% of 846 companies
in the Biotechnology industry
Industry Median: 72.28 vs PHAT: 98.96

Phathom Pharmaceuticals's Days Sales Outstanding declined from Mar. 2024 (131.63) to Mar. 2025 (120.24).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

Phathom Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for Phathom Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phathom Pharmaceuticals Days Sales Outstanding Chart

Phathom Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Sales Outstanding

Get a 7-Day Free Trial

876.11

133.56

Phathom Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Days Sales Outstanding	Get a 7-Day Free Trial															131.63	91.92	89.09	92.05	120.24

Competitive Comparison of Phathom Pharmaceuticals's Days Sales Outstanding

For the Biotechnology subindustry, Phathom Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Phathom Pharmaceuticals's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phathom Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Phathom Pharmaceuticals's Days Sales Outstanding falls into.

Save Embed

;

Save Embed

;

Phathom Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Phathom Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as

	Days Sales Outstanding (A: Dec. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )	/	Revenue (A: Dec. 2024 )	*	Days in Period
=	( (1.637	+	38.797)	/	2 )	/	55.252	*	365
=	20.217					/	55.252	*	365
=	133.56

Phathom Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding (Q: Mar. 2025 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2024 )	+	Accounts Receivable (A: Mar. 2025 ))	/	count )	/	Revenue (A: Mar. 2025 )	*	Days in Period
=	( (38.797	+	36.364)	/	2 )	/	28.519	*	365 / 4
=	37.5805					/	28.519	*	365 / 4
=	120.24

Phathom Pharmaceuticals (NAS:PHAT) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Phathom Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Phathom Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Phathom Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phathom Pharmaceuticals Inc (NAS:PHAT) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Campus Drive, Suite 102, Florham Park, NJ, USA, 07932

Website

https://www.phathompharma.com

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Executives

Molly Henderson	officer: CFO and CBO	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Asit Parikh	director	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Azmi Nabulsi	officer: Chief Operating Officer	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Terrie Curran	director	C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Frank Karbe	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
David A Socks	director, officer: President, CEO, Treas. & Sec.	C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Anthony J. Guzzo	officer: VP, Chief Accounting Officer	C/O US SHIPPING PARTNERS L.P., 399 THORNALL STREET, EDISON NJ 08837
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Todd P. Branning	officer: Chief Financial Officer	C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Mark Stenhouse	director	5505 ENDEAVOR LANE, MADISON WI 53719
Michael F Cola	director	435 DEVON PARK BUILDING 800, WAYNE PA 19087-1945
Frazier Life Sciences Ix, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Jonathan S. Edwards	director	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116